The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Hulio, a biosimilar to Humira, for the treatment of a number of chronic inflammatory diseases including ankylosing spondylitis. A final decision by the European Commission is expected in October. If approved, the agency would grant marketing authorization…
Inhibiting IL-23, a molecule involved in inflammation, was not found to be clinically meaningful to treat ankylosing spondylitis, according to the results from a Phase 2 trial. The study, “Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study,” was…
Higher levels of fatigue are related to the degree of disability at work among ankylosing spondylitis (AS) patients treated with the biologic therapy Enbrel (etanercept), an observational study shows. The study, “…
Women with ankylosing spondylitis (AS) report more severe disease and a poorer quality of life than men, but note comparable improvements in health after starting treatment with TNF inhibitors, a study suggests. Women switch their anti-TNF medications more often, but male patients have a faster spinal deterioration,…
The European Commission has approved Sandoz’s biosimilar Zessly (infliximab) to treat all indications of its reference medicine Remicade (infliximab), including ankylosing spondylitis (AS). “The European Commission approval for Zessly is a key milestone in bringing this important medicine to appropriate patients,” Richard Francis, CEO of Sandoz,…
Treatment with Eli Lilly’s monoclonal antibody Taltz (ixekizumab) significantly improved the signs and symptoms of ankylosing spondylitis in patients participating in a Phase 3 clinical trial, results show. The study, called COAST-W (NCT02696798), met its primary and major secondary endpoints, Eli Lilly said in a news release. COAST-W, the second Phase 3…
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) in addition to tumor necrosis factor (TNF) inhibitors provides stronger long-term protective effects in patients with ankylosing spondylitis, according to recent clinical trial results. The combo therapy prevented radiographic progression of the disease significantly during a four-year period compared to NSAIDs or…
Ontario, along with other regions in Canada, will now reimburse Cosentyx (secukinumab) under its public drug program for certain adult patients with ankylosing spondylitis (AS) and active psoriatic arthritis (PsA), Novartis Pharmaceuticals Canada recently announced. In addition to Ontario, Cosentyx will also be available through the public…
Latest clinical data on Cosentyx (secukinumab) demonstrates its long-term potential to prevent radiographic progression and improve the quality of life of patients with ankylosing spondylitis. Several relevant studies were presented recently at 2018 Annual European Congress of Rheumatology (EULAR), held in Amsterdam, The Netherlands. Cosentyx is a specific…
The investigative therapy bimekizumab showed significant potential in reducing disease activity and it provided clinically meaningful improvements in ankylosing spondylitis (AS) patients, according to Phase 2b clinical trial data. UCB Pharma recently presented the trial’s findings in a study, “Dual Neutralisation of IL-17a and IL-17F with Bimekizumab in…
Get regular updates to your inbox.